Plus Therapeutics Plunges 5.43% on Disappointing Q1 Earnings

On August 12, 2025, Plus Therapeutics experienced a significant drop of 5.43% in pre-market trading, reflecting investor concerns and market sentiment.

Plus Therapeutics recently released its Q1 2025 earnings report, which showed an EPS of -$0.56, falling short of analysts' expectations of -$0.17 by $0.39. This disappointing performance has raised questions about the company's financial health and future prospects.

As the company approaches its 2025Q2 earnings report, analysts are predicting a challenging quarter, with potential declines in revenue and earnings. This cautious outlook has contributed to the recent drop in stock price, as investors brace for further negative news.

Despite the current challenges, Plus Therapeutics has a consensus price target of $10.83, suggesting a potential upside for investors who are willing to take on the risk. However, the company's competitors and alternatives may offer more stable investment opportunities in the current market environment.